category,datetime,headline,id,image,related,source,summary,url
company,1768570495,"Incyte: Buy For The Turnaround, Stay For The Pipeline",138154559,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1493093304/image_1493093304.jpg?io=getty-c-w1536,INCY,SeekingAlpha,"Incyte Corporation rated Strong Buy: Jakafi resilience, 45% ex-Jakafi growth, pipeline catalysts and low 13.7x EPS valuation. Click for this INCY stock update.",https://finnhub.io/api/news?id=456188319d021ee8f3018e2f6692fa748f149defd0b462c48dbf614e0d92bf2b
company,1768566072,XPH: Healthcare Dashboard For January,138153468,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1434365911/image_1434365911.jpg?io=getty-c-w1536,INCY,SeekingAlpha,The State Street SPDR S&P Pharmaceuticals ETF provides equal-weight exposure and cuts single-stock risk. Click here to read my latest analysis of XPH.,https://finnhub.io/api/news?id=88a66b183c88d1dec9678cebfd94abf7fdd27ceb7d9b4ff3369fa886b09cba9c
company,1768551357,Incyte's Pipeline Potential Signals Massive Upside For Investors,138151446,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2150976233/image_2150976233.jpg?io=getty-c-w1536,INCY,SeekingAlpha,"Incyte (INCY) outlook: profitable biotech with expanding Opzelura/oncology growth, key 2026â2030 catalysts, and 33% upsideâread now.",https://finnhub.io/api/news?id=bfc277e926fb5597603729f2f4de467706e75e48bf683b6c28b02a363f3dcaf0
company,1768538026,2 Mid-Cap Stocks with Exciting Potential and 1 We Question,138156421,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,INCY,Yahoo,"Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.",https://finnhub.io/api/news?id=554f01854135ada2da441eaced81614fa17103aa2d638d70f162916bbac01283
